Deborah M. Stephens,
DO
Languages Spoken: English, Spanish
Languages Spoken: English, Spanish
Deborah Stephens, DO joined the Division of Hematology and Hematologic Malignancies as an Assistant Professor in 2014. She completed her internal medicine residency at Cleveland Clinic and fellowship training at Ohio State University. Dr. Stephens’s clinic focuses on patients with chronic lymphocytic leukemia (CLL) and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL.. She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials there. Her research has been widely published in influential journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. She is a member of the editorial board for the Journal of Clinical Oncology. On a national level, she is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is the Physician Leader of the SWOG CLL Working Group Committee, which is a group of CLL experts from academic centers around the country who plan and implement national clinical trials to improve the standard-of-care for CLL patients across the country. Dr. Stephens is also a member of the medical board for the CLL Society, which is the largest patient-led CLL group in the country. The sum of Dr. Stephens's experiences demonstrate her deep commitment to improve the care of patients with CLL and lymphoma.
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.9/ 5
Care provider's effort to include me in decisions
4.9/ 5
Wait time at clinic
4.5/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
May 12, 2022
HUNTSMAN CANCER CENTER
I learned more about my specific problems and was given guidance without feeling forced to do something.
UofU Patient
April 28, 2022
HUNTSMAN CANCER CENTER
Excellent care
UofU Patient
April 14, 2022
HUNTSMAN CANCER CENTER
Dr Stephens is a compassionate and smart doctor who involves her patients in their own care. A great listener!
UofU Patient
April 14, 2022
HUNTSMAN CANCER CENTER
Dr. Stephens is awesome. She is extremely knowledgeable and well informed, but kind and friendly as well.
UofU Patient
April 08, 2022
HUNTSMAN CANCER CENTER
Dr. Stevens is such a wonderful person. The care for each person is amazing. Would not go to anyone else
UofU Patient
March 17, 2022
HUNTSMAN CANCER CENTER
Dr Stephens is the best!
UofU Patient
March 12, 2022
HUNTSMAN CANCER CENTER
Dr Stephens is amazing! She is very friendly, encouraging and very knowledgeable. Highly recommend her for anyone with CLL.
UofU Patient
February 19, 2022
HUNTSMAN CANCER CENTER
Dr. Stephens is amazing! She is easy to talk to and I definitely feel like an active participant in my care. As a patient I feel heard as my questions and concerns are answered and addressed. Dr. Stephens strives to keep patients informed and educated--which helps empower patients and alleviate fears. She is always encouraging and reassuring. I am so grateful to have her as my care provider.
UofU Patient
February 12, 2022
HUNTSMAN CANCER CENTER
Dr Stephens is always caring and helpful.
UofU Patient
February 10, 2022
HUNTSMAN CANCER CENTER
Very grateful for Dr Stephens care.
UofU Patient
December 27, 2021
HUNTSMAN CANCER CENTER
The doctor addressed my questions and issues in a very effective manner. It is always an informative and comfortable situation.
UofU Patient
December 25, 2021
HUNTSMAN CANCER CENTER
Great experience
UofU Patient
December 10, 2021
HUNTSMAN CANCER CENTER
Doctor is very good.
UofU Patient
December 09, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens is a great communicator. She always listens to my concerns and opinions. She explains things thoroughly and I always feel heard as a patient.
UofU Patient
December 07, 2021
HUNTSMAN CANCER CENTER
Dr Stevens is exceptional in all areas, technical and bedside manner.
UofU Patient
December 06, 2021
HUNTSMAN CANCER CENTER
Dr Stephens spent an extensive amount of time in explaining and discussing my proposed treatment.
UofU Patient
November 25, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens is simply the best! I am so fortunate to have her as my physician. She is almost like a friend. She always remembers things that are happening in my life and asks sincere questions about how I'm feeling -- emotionally! Sadly we are moving and I will need to change my health care and I can't begin to tell you how much I will miss Dr. Stephens. I look forward to my visits with her -- isn't that how it should be?
UofU Patient
November 13, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens always gives us her full, focus, care, time and attention as if I am her only patient
UofU Patient
November 04, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens is a wonderful physician. I'm grateful to have her as my caregiver.
UofU Patient
November 02, 2021
HUNTSMAN CANCER CENTER
Dr Stephens is compassionate and very knowledgeable about CLL. I greatly appreciate the time and care she gives me during each visit.
UofU Patient
October 04, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens for President
UofU Patient
August 29, 2021
HUNTSMAN CANCER CENTER
I recommend Huntsman and dr Stevens every chance I get
UofU Patient
August 13, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens is an outstanding physician. She is very approachable, caring and knowledgeable.
UofU Patient
August 05, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
July 01, 2021
HUNTSMAN CANCER CENTER
Dr. D. Stephens was FABULOUS!!!! She listened, she was kind, she was extremely knowledgeable!!! Its difficult to explain how great she was on multiple levels! I left Huntsman so relieved, and informed!!
UofU Patient
May 21, 2021
HUNTSMAN CANCER CENTER
excellent
UofU Patient
May 20, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens has always been kind and compassionate in my care.
UofU Patient
May 03, 2021
HUNTSMAN CANCER CENTER
Dr Stevens was very very concise and very detailed in the explanations of my treatment plan and things that I should do
UofU Patient
May 01, 2021
HUNTSMAN CANCER CENTER
I am very grateful to be under the care of Dr. Stephens
UofU Patient
April 16, 2021
HUNTSMAN CANCER CENTER
Really like Dr Stephens, very caring, kind, and comes across as being very genuine.
UofU Patient
March 29, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens is superlative in every respect. She is the gold-standard for patient care, compassion, patience, competence, expertise, and listening.
UofU Patient
March 25, 2021
HUNTSMAN CANCER CENTER
Great
UofU Patient
March 18, 2021
HUNTSMAN CANCER CENTER
Deborah Stephens was very caring. In fact, she wrote in longhand the information she wanted me to understand about CLL. That is the first I have seen a care provider go to such lengths to be understood. My kudos to Deborah Stephens.
UofU Patient
March 04, 2021
HUNTSMAN CANCER CENTER
I have been dealing with CLL for 23 years. This was the most satisfying and worthwhile visit I have had with a doctor concerning my condition in that entire time.
UofU Patient
February 26, 2021
HUNTSMAN CANCER CENTER
Dr Stephen's is an exceptional caregiver: top in her field, listens to the patient, clear in discussing care options and in answering questions. She has a good sense of humor and takes all the need time for the patient and she is supported with the incredible resources The Huntsman has to offer.
UofU Patient
January 28, 2021
HUNTSMAN CANCER CENTER
I've never had such professional compassion care
UofU Patient
January 17, 2021
HUNTSMAN CANCER CENTER
Doctor Deborah Stephens is a gifted, caring, intelligent Doctor and an even better compassionate women. I literally have quick grown to totally trust her in providing me the best care and options for treatment when the time comes. I consider this more than just a coincidence.
UofU Patient
January 07, 2021
HUNTSMAN CANCER CENTER
very pleased
UofU Patient
December 24, 2020
HUNTSMAN CANCER CENTER
best care around
UofU Patient
December 17, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
December 14, 2020
HUNTSMAN CANCER CENTER
You all are "AWESOME"
UofU Patient
December 05, 2020
HUNTSMAN CANCER CENTER
They are all great to work with.
UofU Patient
December 01, 2020
HUNTSMAN CANCER CENTER
Dr. Stephens is amazing! She is very caring and knowledgeable. In addition, she takes the time to answer all my questions and includes me in decisions. I have complete confidence in her care and I highly recommend her to others.
UofU Patient
November 29, 2020
HUNTSMAN CANCER CENTER
Dr. Stephen's is outstanding!
UofU Patient
November 17, 2020
HUNTSMAN CANCER CENTER
they were very rhoroufh
UofU Patient
October 11, 2020
HUNTSMAN CANCER CENTER
If all doctors were as good as Doctor Stephens all patients would have great care.
UofU Patient
October 09, 2020
HUNTSMAN CANCER CENTER
only the very best
UofU Patient
October 04, 2020
HUNTSMAN CANCER CENTER
Dr Stephens is great. She works with me, not on me.
Languages Spoken: English, Spanish
Deborah Stephens, DO joined the Division of Hematology and Hematologic Malignancies as an Assistant Professor in 2014. She completed her internal medicine residency at Cleveland Clinic and fellowship training at Ohio State University. Dr. Stephens’s clinic focuses on patients with chronic lymphocytic leukemia (CLL) and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL.. She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials there. Her research has been widely published in influential journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. She is a member of the editorial board for the Journal of Clinical Oncology. On a national level, she is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is the Physician Leader of the SWOG CLL Working Group Committee, which is a group of CLL experts from academic centers around the country who plan and implement national clinical trials to improve the standard-of-care for CLL patients across the country. Dr. Stephens is also a member of the medical board for the CLL Society, which is the largest patient-led CLL group in the country. The sum of Dr. Stephens's experiences demonstrate her deep commitment to improve the care of patients with CLL and lymphoma.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Education History
| Fellowship | The Ohio State University Medical Center Hematology & Oncology Chief Fellow, 2014 |
| Residency | The Ohio State University Internal Medicine Resident, 2010 |
| Residency | Cleveland Clinic Internal Medicine Resident, 2009 |
| Professional Medical | Kansas City University of Medicine Osteopathic Medicine D.O., 2007 |
| Undergraduate | The University of Iowa Health Sciences B.S., 2003 |
Selected Publications - Journal Articles
Journal Article
- Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA (2021). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clin Cancer Res, 28(15), 3242-3247.
- Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg JW (2022). Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica.
- Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H (2022). NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw, 20(6), 622-634.
- Hu R, Wei W, Mian A, Gonter-Aubin K, Kabel C, Mato A, Stephens DM, Hanlon A, Khajavian S, Shadman M, Brander D, Madanat Y, Park JH, Tallman M, Pinilla-Ibarz J, Hill BT (2022). Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. Eur J Haematol, 108(5), 379-382.
- Black GS, Huang X, Qiao Y, Tarapcsak S, Rogers KA, Misra S, Byrd JC, Marth GT, Stephens DM, Woyach JA (2022). Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients. Blood, 140, 401-405.
- Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Malecek MK, Watkins MP, Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, Evens AM, Shah M, Ahmed S, Stephens DM, Allen P, Tees MT, Karmali R, Cheson BD, Yazdy MS, Strouse C, Bailey NA, Pagel JM, Ramchandren R (2021). Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clin Lymphoma Myeloma Leuk, 22, e435-e442.
- Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato A, Winter A, Hill B, Gaballa S, Danilov A, Phillips T, Brander DM, Smith SM, Davids M, Rogers K, Glenn MJ, Byrd JC (2021). Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica, 106(11), 2845-2852.
- Furman RR, Byrd JC, Owen RG, OBrien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer MJS, Streetly MJ, Sun C, Rule S, Wang M, Ghia P, Jurczak W, Pagel JM, Sharman JP (2021). Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 35(11), 3201-3211.
- Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG (2021). Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood, 139, 1794-1806.
- Stephens DM, Byrd JC (2020). Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood, 138(13), 1099-1109.
- Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR (2021). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica, 107, 1335-1346.
- Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA (2021). Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood, 139, 413-423.
- Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov AV (2021). The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clin Cancer Res, 27(17), 4814-4824.
- Byrd JC, Woyach JA, Furman RR, Martin P, OBrien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG (2020). Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, 137(24), 3327-3338.
- Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov AV (2021). The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clin Cancer Res.
- Shah H, Stephens D, Seymour J, Maddocks K (2021). Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas. Am Soc Clin Oncol Educ Book, 41, 1-18.
- Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov AV (2020). Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transplant Cell Ther, 27(1), 46-52.
- Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp NJ (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. 5, 189-199.
- Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD 3rd, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW (2020). Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol, 38(26), 3003-3011.
- Koffman B, Mato A, Byrd J, Danilov A, Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids M, Pagel JM, Shadman M (2020). A survey of CLL experts opinion on management of patients during the COVID-19 pandemic. J Clin Oncol, E199-E203..
- Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, OBrien S, Furman RR (2018). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood, 135(15), 1204-1213.
- Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer MA, Sundar H (2020). Chronic lymphocytic leukemia/small lymphocytic lymphoma, Version 4.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 18(2), 185-217.
- Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H (2020). Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(2), 185-217.
- Gordon MJ, Sitlinger A, Salous T, Alqahtani H, Churnetski M, Rivera X, Wisniewski P, Cohen J, Patel K, Shadman M, Choi M, Hill B, Stephens DM, Persky D, Brander D, Danilov AD (2020). A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: results from a multicenter retrospective cohort study. Leuk Res Treatment, 89.
- Stephens DM (2019). Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia. Blood, 134(20), 1691-1696.
- Stephens DM, Li H, Schder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW (2019). Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 134(15), 1238-1246.
- Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ (2019). Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. Br J Haematol, 186(2), 255-262.
- Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC (2018). Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv, 3(9), 1553-1562.
- Stephens DM, Byrd JC (2019). How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood, 133(12), 1298-1307.
- Stephens DM (2019). Highs and lows of minimal residual disease in CLL. Blood, 133(5), 386-388.
- Havard R, Stephens DM (2018). Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. Curr Hematol Malig Rep, 13(6), 534-542.
- Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Jones JA (2018). A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol, 180(2), 259-266.
- Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H (2017). Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15, 1414-1427.
- Giulino-Roth L, ODonohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP (2017). Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol, 179(5), 739-747.
- Stephens DM (2017). Brentuximab: is it time for a new "B" in ABVD? Blood, 130(11), 1281-1282.
- Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM (2017). PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood, 130(2), 221-228.
- Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC (2016). Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study. Blood, 128(22), 638.
- Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW (2016). Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park), 30(11), 970-4, 980-1, C3.
- Haverkos BM, Schowinksy J, Kaplan J, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Flowers MED, Fensky TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia MH, Brown S, Armand P, Merryman RW, Bachanova V, Stephens DM, Nakamura R, Gutman JA, Devine SM (2016). Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. Blood, 128(22), 1163.
- Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM (2016). Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol, 34(25), 2997-3004.
- Stephens DM, Goodrich AL (2016). Risk-Stratified Treatment in Chronic Lymphocytic Leukemia. J Adv Pract Oncol, 7(3), 314-317.
- Luo C, Deng Z, Li L, Clayton F, Chen AL, Wei R, Miles R, Stephens DM, Glenn M, Wang X, Jensen PE, Chen X (2016). Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. Oncotarget, 7(11), 12806-22.
- Byrd JC, Harrington B, OBrien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR (2016). Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med, 374(4), 323-32.
- Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, OBrien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC (2015). Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Am J Hematol, 90(11), 967-9.
- Stephens DM, Spurgeon SE (2015). Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol, 6(5), 242-52.
- Miller CR, Stephens D, Ruppert AS, Racke F, McFaddin A, Breidenbach H, Lin HJ, Waller K, Bannerman T, Jones JA, Woyach JA, Andritsos LA, Maddocks K, Zhao W, Lozanski G, Flynn JM, Grever M, Byrd JC, Heerema NA (2015). Jumping translocations, a novel finding in chronic lymphocytic leukaemia. Br J Haematol, 170(2), 200-7.
- Rogers KA, Salem G, Stephens DM, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Huang Y, Ruppert AS, Jones JA (2015). A single-institution retrospective cohort study of patients treated with R-EPOCH for Richter’s transformation of chronic lymphocytic leukemia. Blood, 126(23), 2951.
- Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC (2014). Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia, 28(6), 1365-8.
- Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, OReilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC (2014). Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs, 6(3), 749-55.
- Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM (2013). Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res, 37(10), 1195-9.
- Stephens DM, Stark A, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC (2013). Changing the treatment paradigm for previously treated chronic lymphocytic leukemia patients with del(17p) karyotype. Blood, 122(21), 2872.
- Stephens DM, Byrd JC (2013). Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. Oncology (Williston Park), 26(11), 1044-54.
- Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd JC (2012). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 97(3), 423-7.
- Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, and Byrd JC (03/01/2012). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 97(3), 423-427.
- Mickelson DM, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, Copelan EA (2011). Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplant, 46(1), 84-9.
- Mickelson DM, Hatem S, and Copelan E (02/01/2010). Granulocyte Simulating-Colony Factor-Associated Splenic Artery Rupture. Leuk Lymphoma, 51(2), 335-337.
- Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. . (Epub ahead of print) J Natl Cancer Inst.
- Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR (Pending). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: Pooled analysis of 762 patients. 2021 Apr. Accepted for publication. (Epub ahead of print) Leukemia.
- Abbott J, Corean J, Snyder AM, Florell SR, Miles R, Stephens DM, Wada DA (Pending). Clinical and histologic spectrum of cutaneous hypersensitivity reactions in CLL/SLL patients with identification of T-cell papulosis of B-cell malignancy as a distinct subset. 2021 Mar. Submitted for review. (Epub ahead of print)
Review
- Stephens DM, Byrd JC (2020). Next-Generation Bruton Tyrosine Kinase Inhibitors. [Review]. Am J Clin Oncol, JCO2001594.
- Shadman M, Stephens DM (2020). Debate: What is optimal first-line therapy for chronic lymphocytic leukemia? [Review]. J Natl Compr Canc Netw, 18(7.5), 993-997.
- Stephens DM (2019). Venetoclax and obinutuzumab for front-line treatment of chronic lymphocytic leukemia. [Review]. Blood, 134(20), 1691-1696.
- Stephens DM (2019). Highs and lows of minimal residual disease in CLL. [Review]. Blood, 133(5), 386-388.
- Stephens DM, Byrd JC (2019). How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. . [Review]. Blood, 133(12), 1298-1307.
- Harvard R, Stephens DM (2018). Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. [Review]. Curr Hematol Malig Rep, 13(6), 534-542.
- Stephens DM, Smith SM (2018). Diffuse large B-cell lymphoma-Who should we FISH? [Review]. 2, 2616-2695.
- Voorhies BN, Stephens DM (2017). What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017? [Review]. Curr Treat Options Oncol, 18(2), 12.
- Stephens DM, Goodrich AL (2016). Risk-Stratified Treatment in Chronic Lymphocytic Leukemia. [Review]. J Adv Pract Oncol, 7(3), 314-317.
- Stephens DM, Sweetenham JW (04/11/2015). Clinical controversies of double-hit lymphoma. [Review]. Am J Hematol Oncol, 11(4), 10-16.
- Stephens DM, Byrd JC (2013). Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy. [Review]. Hematol Oncol Clin North Am, 27(2), 303-27.
- Stephens DM, Byrd JC (11/1/2012). Chronic lymphocytic leukemia with del(17p13.1): A distinct clinical subtype requiring novel treatment approaches. [Review]. Oncology, 11, 1044-1054.
- Stephens DM, Byrd JC (2012). Ask the hematologists: Is there a standard of care for treating older patients with chronic lymphocytic leukemia? [Review]. 9(4), 4.
- Stephens DM, Byrd JC (2012). Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. [Review]. Oncology, 26(11), 1044-1054.
- Mickelson DM, Mady E, and Teng K (2009). A 43 year-old woman with chest pressure: a review of hypercoagulable states. [Review]. Cleve Clin J Med, 76(3), 191-8.
- Stephens DMByrd JC (Submitted). Resistance to Bruton’s Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies Next-Generation Bruton Tyrosine Kinase Inhibitors. Accepted for publication. [Review]. Blood.
- Shah H, Stephens DM, Seymour J, Maddocks K (Pending). Incorporating novel targeted and immunotherapeutic agents in treatment of B-cell lymphomas. 2021 Feb. Accepted for publication. [Review]. J Clin Oncol.
Conference Proceedings
- Gordon M, Kaempf A, Sitlinger A, Salous T, Alqahtani H, Churnetski MC, Wisniewski P, Rivera X, Patel K, Persky D, Cohen JB, Choi M, Hill BT, Shadman M, Stephens DM, Brander D, Park B, Danilov AV (2020). The chronic lymphocytic leukemia comorbidity index (CLL-CI) predicts survival and tolerance of ibrutinib therapy in patients with CLL: A multicenter retrospective cohort study. . American Society of Hematology Meeting, San Diego, California.
- Orellana-Noia V, Reed D, Sen J, Barlow C, Malecek M, Watkins M, Kahl B, Spinner M, Advani R, Voorhees T, Snow A, Grover N, Ayers A, Romacik J, Liu Y, Huntington S, Chavez J, Saeed H, Lazaryan A, Raghunathan V, Spurgeon S, Ollila T, Del Potro C, Olszewski A, Ayers E, Landsburg D, Echaier B, Lee J, Kamdar M, Caimi P, Fu T, Liu J, David K, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek A, Smith S, Yellala A, Kallam A, Nakhoda S, Khan N, Cohen J, Portel C (2020). Prophylaxis during front-Line therapy in aggressive non-Hodgkin lymphomas: Real-world outcomes and practice patterns from 19 US academic institutions. . American Society of Hematology Meeting, San Diego, California.
- Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Wierda WG (2020). Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of TRANSCEND CLL 004, including high-risk and ibrutinib-treated patients. American Society of Hematology Meeting, San Diego, California.
- Wierda WG, Dorritie KA, Munoz J, Stephens DM, Solomon S, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Siddiqi T (2020). TRANSCEND CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). American Society of Hematology Meeting, San Diego, California.
- Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Baek M, Lezhava T, Kuptsova-Clarkson N, Moslehi J, Furman RR (2020). Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with chronic lymphocytic leukemia. American Society of Hematology Meeting, San Diego, California.
- Karmali R, Abramson JS, Stephens DM, Barnes J, Kaplan J, Winter JN, Ma S, Gao J, Petrich A, Hochberg E, Takvorian T, Kuhr F, Nelson V, Gordon LI, Pro, B (2020). Ibrutinib maintenance (I-M) following frontline intensive induction in mantle cell lymphoma (MCL): assessment of efficacy, safety and changes in minimal residual disease. American Society of Hematology Meeting, San Diego, California.
- Blachly JS, Lamanna N, Stephens DM, Ye CJ, Niesman M, Zhang K, Woyach JA (2020). Initial results from a phase 1 dose escalation study evaluating MS-553, a novel, selective PKC-beta inhibitor, in relapsed or refractory CLL/SLL patients. American Society of Hematology Meeting, San Diego, California.
- Wierda WGDorritieKA, Munoz J, Stephens DM, Solomon S, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Siddiqi T (2020). TRANSCEND CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T cell product, in combination with ibrutinib for patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). . American Society of Clinical Oncology Meeting, Chicago, Illinois.
- Rogers KA, Wei L, Bhatt S, Jones D, Seymour E, Stephens DM, Ye C, Byrd JC, Woyach JA (2019). A multicenter study of ibrutinib resistance development and intervention with venetoclax. American Society of Hematology Meeting, Orlando, Florida.
- Hamid MS, Rutherford SC, Kim S, Bartlett N, Kate-Malecek M, Watkins M, Maddocks K, Bond D, Feldman T, Magarelli G, Advani R, Spinner M, Ahmed S, Stephens DM, Allen P, Patel K, Tees MT, Karmali R, Cheson B, Yazdy MS, Link B, Strouse C, Pagel JM, Ramchandren R (2019). Risk adapted approach for PET-2 positive Hodgkin lymphoma in the real world setting. . American Society of Hematology Meeting, Orlando, Florida.
- Karmali R, Abramson J, Stephens DM, Barnes J, Kaplan J, Winter J, Ma S, Gao J, Petrich A, Hochberg E, Takvorian T, Kuhr F, Nelson V, Gordon LI, Pro B (2019). Interim safety, response and MRD evaluation in mantle cell lymphoma (MCL) patients treated with frontline intensive induction chemotherapy followed by ibrutinib maintenance. . American Society of Hematology Meeting, Orlando, Florida.
- Byrd JC, Wierda W, Schuh, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, OBrien S, Furman RR (2019). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: 45-Month follow-up of a phase 2 study. . American Society of Hematology Meeting, Orlando, Florida.
- Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Dubovsky JA, Rytlewski J, Yang L, Wierda WG (2019). Rapid undetectable MRD responses in patients with relapsed/refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treated with lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T Cell product: Updated results from TRANSCEND CLL 004, a phase 1/2 study including patients with high-risk disease previously treated with ibrutinib. . American Society of Hematology Meeting, Orlando, Florida.
- Kittai A, Gordon M, Mian A, Fitzgerald L, Bishop J, Stephens DM, Nagle S, Hill B, Danilov A (2019). Comorbidities predict inferior survival in patients receiving CAR T-cell therapy for relapsed/refractory DLBCL: A multicenter retrospective analysis. . American Society of Hematology Meeting, Orlando, Florida.
- Woyach JA, Stephens DM, Flinn I, Bhat S, Savage R, Chai F, Eathiraj S, Granlund L, Szuszkiewicz L, Schwartz B, Byrd JC (2019). Final results of a phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-Cell lymphoid malignancies. American Society of Hematology Meeting, Orlando, Florida.
- Persky DO, Li H, Stephens DM, Park SI, Bartlett N, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Friedberg JW (2019). PET-Directed therapy for patients with limited-stage diffuse large B-Cell lymphoma - Results of Intergroup NCTN Study S1001. . American Society of Hematology Meeting, Orlando, Florida.
- Stephens, DM, Huang Y, Ruppert AS, Agyeman A, Hu B, Turner N, Vadeboncoeur R, Rogers K, Bhat S, Basem W, Jaglowski SM, Hockman H, Glenn MJ, Lapalombella R, Byrd JC, Woyach J (2019). Selinexor combined with ibrutinib demonstrates tolerability and efficacy in advanced B-cell malignancies: A phase I study. . American Society of Hematology Meeting, Orlando, Florida.
- Siddiqi T, Dorritie KA, Soumerai JD, Stephens DM, Dubovsky JA, Gillenwater HH, Gong L, Thorpe J, Yang L, Wierda WG (2019). TRANSCEND 004 CLL: Minimal residual disease negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. . American Society of Clinical Oncology Meeting, Chicago, Illinois.
- Karmali R, Abramson JS, Stephens DM, Barnes JA, Kaplan JB, Winter JN, Ma S, Petrich AM, Hochberg EP, Takvorian T, Nelson V, Gordon LI, Pro B (2019). Ibrutinib maintenance following induction for untreated mantle cell lymphoma: Initial safety report. . American Society of Clinical Oncology Meeting, Chicago, Illinois.
- Byrd J, Woyach J, Furman R, Martin P, OBrien S, Brown J, Stephens D, Barrientos J, Devereux S, Hillmen P, Pagel J, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda W (2019). Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase 2 study demonstrating durable remission and long-term tolerability. . European Hematology Association Meeting, Frankfurt, Germany.
- Byrd JC, Woyach JA, Furman RR, Martin P, OBrien SM, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillemen P, Pagel JM, Chen D, Hamdy A, Izumi R, Patel P, Wan MH, Jain N, Wierda WG (December 2018). Acalabutinib in treatment-naive chronic lymphocytic leukemia: Updated results from phase 1/2 ACE-CL-001 study. American Society of Hematology Meeting, San Diego, California.
- Koffman B, Dennison B, Kennard K, Furman R, Byrd J, Pagel J, Davids MS, Nabhan C, Kay N, Brander D, Siddiqi T, Hill B, Pinilla-Ibarz J, Cheson B, Rosen ST, Wierda WG, Stephens DM, Awan FT, Choi MY, Mato AR (2018 Jun). A US-Based survey: The experiences and perspectives of 1147 chronic lymphocytic leukemia patients. European Hematology Association Meeting, Stockholm, Sweden.
- Geer M, Shango M, Till B, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Roberts E, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ (2017). Multicenter retrospective study of features and outcomes of patients with intravascular DLBCL treated at academic institutions within the United States. American Society of Hematology Meeting, Atlanta.
- Byrd JC, Wierda W, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Charuworn P, Hamdy A, Izumi R, Patel P, Wan MH, Furman RR (2017). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: Updated results from the phase 1/2 ACE-CL-001 Study. American Society of Hematology Meeting, Atlanta, Georgia.
- Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd JC (2016). Acalabrutinib monotherapy in patients with ibrutinib: results from the phase 1/2 ACE-CL-001 clinical study. American Society of Hematology Meeting, Sand Diego.
- Haverkos BM, Schowinksy J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, Fenske TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova V, Stephens DM, Nakumura R, Gutman J, Devine SM (2016 Dec). Checkpoint blockade for treatment of lymphoma following allogeneic stem cell transplant: use may be complicated by onset of severe acute graft versus host disease. American Society of Hematology Meeting, San Diego.
- Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd JC (2016 Dec). Acalabrutinib monotherapy in patients with ibrutinibi: results from the phase 1/2 ACE-CL-001 clinical study. American Society of Hematology Meeting, San Diego, California.
- Haverkos BM, Schowinksy J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, Fenske TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova V, Stephens DM, Nakumura R, Gutman J, Devine SM (12/03/2016). Checkpoint blockade for treatment of lymphoma following allogeneic stem cell transplant: use may be complicated by onset of severe acute graft versus host disease. American Society of Hematology Meeting, San Diego.
- Stephens DM, Starodub AN, Byrd JC, Wegener, WA, Horne H, Goldenberg, DM, Christian BA (07/15/2016). Subcutaneous injections of IMMU-114 (anti-HLA-DR IgG4 monoclonal antibody): Initial results of a phase I first-in-man study in hematologic malignancies. Pan-Pacific Lymphoma Conference, Poipu, Hawaii.
- Byrd JC, Jones JA, Furman RR, Stephens DM, Devereux S, Brown JR, Hillmen P, Hamdy AM, Wang MH, Patel P, Mittag D, Krantz M, Rothbaum W, Izumi R, OBrien SM, Wierda WG (06/15/2016). Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, in previously untreated chronic lymphocytic leukemia. American Society of Clinical Oncology Annual Meeting, Chicago.
- Wierda WG, Jones JA, Furman RR, Stephens DM, Devereux S, Brown JR, Hillmen P, Hamdy A, Fardis M, Tawashi M, Wang MH, Patel P, Mittag D, Krantz F, Rothbaum W, Izumi R, OBrien S, Byrd JC (2016 Jun). Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, in previously untreated chronic lymphocytic leukemia. European Hematology Association Annual Meeting, Copenhagen, Denmark.
- Byrd JC, Wierda WG, Jones JA, OBrien S, Brown JR, Schuh A, Hillmen P, Stephens DM, Gia P, Devereux S, Chaves J, Barrientos JC, Wan MH, Huang J, Covey T, Navarro T, Hamdy A, Furman RR (2015 Dec). The Bruton tyrosine kinase (Btk) inhibitor ACP-196: Marked activity in relapsed/refractory CLL with a favorable safety profile. American Society of Hematology Meeting, Orlando, Florida.
- Stephens DM, Starodub AN, Byrd JC, Wegener, WA, Horne H, Goldenberg, DM, Christian BA (12/01/2015). Subcutaneous injections of IMMU-114 (anti-HLA-DR IgG4 monoclonal antibody): Initial results of a phase I first-in-man study in hematologic malignancies. Orlando, Florida: American Society of Hematology Meeting.
- Stephens DM, LeBlanc ML, Li H, Miller TP, Puvvada SD, Persky D, Friedberg J, Smith SM (06/19/2015). Continued risk of relapse independent of treatment modality in limted stage diffuse large B-cell lymphoma: Final and long-term analysis of SWOG study S8736. 13th International Conference on Malignant Lymphoma, Lugano, Switzerland.
- Stephens DM, Stark A, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC (2013). Changing the treatment paradigm for previously treated chronic lymphocytic leukemia patients with del(17p) karyotype. New Orleans, LA: American Society of Hematology Meeting.
- Stephens DM, Cheney CM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, OReilly A, Ramachandran A, Tidandapani S, Muthusamy N, and Byrd JC (2013). Ocaratuzumab, a proposed effective and convenient alternative for treatment of chronic lymphocytic leukemia. Cologne, Germany: International Workshop on Chronic Lymphocytic Leukemia.
- Stephens DM, Ruppert AS, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Jones JA, Flynn JM, Grever MR, Hareema N, Muthusamy N, and Byrd JC (06/01/2013). Predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Stockholm, Sweden: European Hematology Association International Congress.
- Stephens DM, Maddocks K, Andritsos L, Baiocchi R, Jones J, Phelps M, Johnson AJ, Smith L, Grever MR, Byrd JC, and Flynn JM (06/01/2012). Phase I feasibility trial of cyclophosphamide, alvocidib (flavopiridol) and rituximab in patients with high-risk b-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Amsterdam, Netherlands: European Hematology Association International Congress.
- Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, and Byrd JC (12/01/2010). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Orlando, Florida: American Society of Hematology Meeting.
- Mickelson D, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, and Copelan E (02/01/2009). T-cell engraftment kinetics following myeloablative and nonmyeloablative regimens for allogeneic hematopoietic stem-cell transplantation. Tampa, Florida: American Society for Blood and Marrow Transplantation.
Commentary
- Stephens DM (2017). Brentuximab: is it time for a new "B" in ABVD? Blood, 130(11), 1281-1282.
- Stephens DM (2016). Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia: An Archaic Intervention or a Necessary Evil? Oncology (Williston Park), 30(6), 539-40.
Case Report
- Shah HR, Stephens DM (2021). Is there a role for anti-CD20 antibodies in CLL? Hematology Am Soc Hematol Educ Program, 2021(1), 68-75.
- Fitzgerald L, Stephens DM (2020). Burkitt Lymphoma Presenting as Cranial Multineuritis Secondary to Primary Neurolymphomatosis: A Diagnostic Challenge. Clin Lymphoma Myeloma Leuk, 20(4), e201-e204.
- Laggis C, Miles R, Stephens DM, Duffy K, Bowen A, Wada D (2019). Cutaneous mantle cell lymphoma histomorphologically mimicking subcutaneous panniculitis-like T-cell lymphoma: Case report. J Cutan Pathol, 46(7), 538-541.
- Fitzgerald LA, Stephens DM (22 June 2017). Seeing Double: A Rare Presentation of Non-Hodgkin Lymphoma. Ann Hematol Oncol, 4(6), 1155.
- Juster-Switlyk K, Smith AG, Kovacsovics T, Stephens D, Glenn M, Palmer CA, Quigley EP 3rd, Kolb N (2017). MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk. Neurology, 88(6), 603-604.
Editorial
Letter
- Stephens DM, Schoder H, Li H, Friedberg J (2020). Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient? [Letter to the editor]. J Nucl Med, 61(11), 1695.
- Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids MS, Pagel JM, Shadman M (2020). Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. [Letter to the editor]. Am J Hematol, 95(8), E199-E203.
Abstract
- Giulino-Roth L, ODonohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberlye MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP (2017). Outcomes of adults, adolescents, and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R therapy: a multicenter retrospective analysis [Abstract]. Hematological Oncology, 35(S2), 61-2.
- Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd JC (12/03/2016). Acalabrutinib monotherapy in patients with ibrutinibi: results from the phase 1/2 ACE-CL-001 clinical study [Abstract]. Blood, 128(22), 638.
- Stephens DM, Ruppert AS, Christian B, Jones J, Flynn JM, Porcu P, Baiocchi R, Byrd JC, Dotson EK, Crawford BS, and Blum KA (2012). Toxicity in patients 65 years with dose adjusted REPOCH for untreated diffuse large B cell lymphoma [Abstract]. Journal of Clinical Oncology, 30(suppl), 15.
- Stephens DM, Ruppert AS, Christian B, Jones J, Flynn JM, Porcu P, Baiocchi R, Byrd JC, Dotson EK, Crawford BS, Blum KA (2012). Toxicity in patients ≥ 65 years with dose adjusted REPOCH for untreated diffuse large B cell lymphoma [Abstract]. Journal of Clinical Oncology (Meeting Abstracts), 30(suppl), 15.